Alerts will be sent to your verified email
Verify Email
FREDUN
|
Fredun Pharma
|
Beta Drugs
|
Wanbury
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
11.84 % | 22.74 % | 58.3 % |
|
5yr average Equity Multiplier
|
2.85 | 1.82 | -1.35 |
|
5yr Average Asset Turnover Ratio
|
1.08 | 1.03 | 1.54 |
|
5yr Avg Net Profit Margin
|
3.9 % | 12.23 % | 5.09 % |
|
Price to Book
|
6.12 | 0.0 | 13.99 |
|
P/E
|
29.43 | 25.18 | 19.28 |
|
5yr Avg Cash Conversion Cycle
|
175.29 Days | 7.75 Days | -103.0 Days |
|
Inventory Days
|
146.68 Days | 46.07 Days | 21.96 Days |
|
Days Receivable
|
142.46 Days | 91.57 Days | 61.39 Days |
|
Days Payable
|
112.95 Days | 119.03 Days | 194.51 Days |
|
5yr Average Interest Coverage Ratio
|
2.62 | 14.42 | 2.13 |
|
5yr Avg ROCE
|
22.71 % | 27.84 % | -37.9 % |
|
5yr Avg Operating Profit Margin
|
9.7 % | 21.76 % | 7.72 % |
|
5 yr average Debt to Equity
|
0.93 | 0.29 | 0.2 |
|
5yr CAGR Net Profit
|
25.5 % | 29.34 % | n/a |
|
5yr Average Return on Assets
|
4.18 % | 12.69 % | 7.92 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
43.06 % | 64.63 % | 43.07 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 62.18 % |
|
Change in Promoter Holding (3 Yrs)
|
-7.28 % | -2.1 % | 3.23 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Fredun Pharma
|
Beta Drugs
|
Wanbury
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|